# Diabetes Research Hub — Monitor Review Report

**Run date:** 2026-06-06 (automated scheduled run)
**Reviewer:** Hub monitor agent
**Scope:** Read-only review of latest script outputs + web check. No files modified.

---

## Executive Summary

A quiet day on the data front. The overnight pipeline (hub_monitor, baseline_clinical_trials, baseline_pubmed_alerts) ran cleanly at 07:04–07:05. **Clinical trials are unchanged** vs. yesterday (0 new, 0 status changes, 0 new results posted). **PubMed added 12 new papers and dropped 10** within the 30-day rolling window. No genuinely breaking diabetes news in the last 7 days — the major regulatory events (Tzield age expansion, orforglipron/Foundayo approval, Awiqli once-weekly insulin) all predate this week and are already in context.

The one housekeeping item worth flagging: the **gap-analysis source data (`literature_gap_data.json`) is from April 20 — 47 days stale**, even though the human-readable report was regenerated June 5. Worth a re-run.

---

## File System Status

All core pipeline outputs are current (generated 2026-06-06 07:04–07:05):

| File | Last modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-06-06 07:05 | Current |
| clinical_trials_latest.json | 2026-06-06 07:04 | Current |
| clinical_trials_summary.md | 2026-06-06 07:04 | Current |
| pubmed_recent_latest.json | 2026-06-06 07:05 | Current |
| pubmed_recent_summary.md | 2026-06-06 07:05 | Current |
| literature_gap_report.md | 2026-06-05 23:25 | Current (manual iterate run) |
| **literature_gap_data.json** | **2026-04-20** | **STALE (47 days)** |
| literature_gap_matrix.xlsx | 2026-04-20 | Stale (47 days) |

Hub totals: 901 files tracked, 3 new, 28 modified, 0 removed. The 28 modified files are the expected nightly regenerations (dashboards, evidence network, citation/PMID validation). The monitor flags "681 result files older than 14 days" — this is almost entirely the archived daily snapshot history (trials + PubMed back to March 15) and prior monitor reports; not actionable.

---

## Clinical Trial Changes

**No change since the 2026-06-05 snapshot:** 0 new trials, 0 removed, 0 status changes, 0 newly posted results (per automated snapshot diff). Corpus holds **802 unique trials** (263 RECRUITING, 124 Phase 3, 290 completed-with-results).

### Key Phase 3 trials under watch (46 Phase 3 currently recruiting)

Cell therapy / cure:
- **NCT06832410** & **NCT04786262** — Vertex, VX-880 / **zimislecel** (stem-cell islet therapy), Phase 3 recruiting. Vertex has signaled FDA/EMA/MHRA regulatory submissions in 2026.

Immunotherapy / disease-modifying (T1D):
- **NCT07222332** & **NCT07222137** — Eli Lilly, **baricitinib** to preserve beta-cell function / delay Stage 3 T1D, Phase 3 recruiting.
- **NCT07088068** — Sanofi, **teplizumab** head-to-head comparison, Phase 3 recruiting.
- **NCT07258394** / **NCT07548996** — Nanjing Medical Univ., dimethyl fumarate for islet preservation.

T2D / metabolic:
- **NCT07076199** — Novo Nordisk, once-weekly **insulin icodec** in T1D, Phase 3 recruiting.
- **NCT07564414** / NCT06534411 — Novo Nordisk, **CagriSema** dose-finding/efficacy.
- **NCT06334133** — vTv Therapeutics, **cadisegliatin** (glucokinase activator) adjunct to insulin — directly relevant to our Glucokinase gap cluster.

### Recently posted results worth reviewing (22 posted since 2026-05-01)

- **NCT05813912** (Novo, once-weekly insulin icodec) — results posted 2026-06-03.
- **NCT04426474** (Lilly, LY3502970 / orforglipron in T2D) — results posted 2026-05-26.
- **NCT04167761** (Stanford, ertugliflozin epicardial-fat cardioprotection) — posted 2026-06-04.
- **NCT05925920** (Metabolics Pharma, ENT-03) — posted 2026-06-01.

---

## PubMed Highlights

30-day rolling window: **167 unique papers** across 16 alert domains. **12 added / 10 dropped** vs. 2026-06-05.

### Cross-domain papers (highest priority — 11 total)

- **PMID 42163482** — Extracellular-vesicle proteins as predictive biomarkers for T1D. *Domains: Stem Cell Cure + Immunotherapy + teplizumab.* (Proteomics — relevant to Tier 1 Multi-Omics Biomarker work.)
- **PMID 42198313** — Diabetes & stroke: GLP-1 therapeutic potential. *Domains: orforglipron + retatrutide + CagriSema.*
- **PMID 42239940** — TMAO + phenylacetylglutamine as biomarkers for diabetic complications. *Domains: Biomarker + Microbiome* (Tier 2 microbiome-metabolite pathway).
- **PMID 42219961** — Multi-omics Mendelian randomization, lipid-metabolism genes. *Domains: Epigenetics + Multi-Omics* (Tier 1 relevant).
- **PMID 42221148** — Teplizumab in Stage 3 T1D, systematic review. *Domains: Immunotherapy + teplizumab.*

### Key-therapy mentions this cycle

teplizumab (5 papers), retatrutide (5), CagriSema (5), icodec (5), dapagliflozin (5), orforglipron (4), baricitinib (4). **zimislecel: 0 papers** — still no peer-reviewed literature flow despite the active Phase 3 program; worth continued monitoring.

### New papers of note (added since 06-05)

- "Dapagliflozin as adjunct to insulin improves time-in-range vs. ..." (Endocrine Practice, Jun 4) — SGLT2 adjunct in T1D.
- "Disproportionality analysis of tirzepatide-associated ketoacidosis" (Endocrine Practice, Jun 4) — safety signal worth noting for the GLP-1/GIP tracking.
- "Upregulation of ADAM19 in dendritic cells … lower C-peptide" (Diabetology & Metab Syndrome, Jun 5) — candidate T1D biomarker.

Volume note: domains are healthy and stable; Drug Repurposing (5) and GLP-1 Pharmacogenomics (3) remain the thinnest streams — consistent with the gap analysis below.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score, joint pubs) from `literature_gap_report.md` — **BRONZE validation, single source, expert confirmation pending**:

1. **Beta Cell Regen × Health Equity** — 100.0 (0 joint pubs)
2. **Insulin Resistance × Islet Transplant** — 100.0 (1)
3. **Islet Transplant × Drug Repurposing** — 100.0 (0)
4. **Islet Transplant × Health Equity** — 100.0 (0)
5. **Gene Therapy × LADA** — 100.0 (0)

### Alignment with Tier 1 contribution areas (per RESEARCH_DOCTRINE.md)

- **Islet Transplant × Drug Repurposing** (#3) maps directly to Tier 1 area #4 (Drug Repurposing Computational Screening). We already have `islet_repurposing_*` outputs — this gap is actionable with existing tooling. The cadisegliatin Phase 3 (NCT06334133) gives it live clinical relevance.
- **× Health Equity** intersections (#1, #4) align with Tier 1 area #6 (Epidemiological / Health Equity analysis) — data is public (GBD, CDC, IDF).
- **Gene Therapy × LADA** (#5) is more exploratory; LADA literature is thin (547 pubs total) and would need expert framing before synthesis.

---

## Breaking News (web check, last 7 days)

No genuinely new high-significance items in the trailing 7 days. For context, the recent regulatory landscape (all already known / pre-dating this week):

- **Tzield (teplizumab)** — FDA approved age expansion to ≥1 year on **2026-04-22** (was ≥8 yr). Sanofi.
- **Foundayo (orforglipron)** — FDA approved in 2026 (oral GLP-1, obesity indication), well ahead of the Jan-2027 PDUFA date. Eli Lilly.
- **Awiqli (insulin icodec)** — approved **2026-03-26** as first once-weekly basal insulin (T2D). Langlara (insulin glargine biosimilar) approved 2026-04-29.
- **Zimislecel (VX-880)** — Vertex on track for **2026 global regulatory submissions**; potential availability as early as 2027. No FDA decision yet. This remains the single highest-impact item to watch for our cure/cell-therapy tracking.

---

## Recommended Actions

1. **Re-run gap analysis.** `literature_gap_data.json` and `literature_gap_matrix.xlsx` are 47 days old (Apr 20). Run: `python project1_literature_gap_analysis.py` to refresh the underlying matrix so the report reflects current PubMed counts.
2. **Pursue the Islet Transplant × Drug Repurposing gap** (Gap Score 100, Tier 1 area #4). We have `islet_repurposing_drug_candidates.json` / `islet_repurposing_network_analysis.json` already — this is the most directly actionable computational contribution in the current top-5.
3. **Review cross-domain paper PMID 42163482** (EV proteins as T1D predictive biomarkers) — overlaps Stem Cell Cure + Immunotherapy + teplizumab and feeds Tier 1 Multi-Omics Biomarker Integration.
4. **Add curated "Notable Trials to Watch" entries** to `clinical_trials_summary.md` (table is empty) — suggest seeding with zimislecel (NCT06832410), the two Lilly baricitinib Phase 3s, and cadisegliatin (NCT06334133).
5. **Monitor zimislecel** for (a) first peer-reviewed publications (0 to date) and (b) confirmation of the 2026 FDA/EMA/MHRA submission — highest-impact event in the cure pipeline.
6. **Flag for safety tracking:** new tirzepatide-associated ketoacidosis disproportionality paper (Jun 4) — relevant to the GLP-1/GIP therapy domain.

---

*Evidence note (per Research Doctrine): all gap classifications above remain BRONZE (single analytical source). Trial and PubMed counts are directly reproducible from ClinicalTrials.gov API v2 and PubMed E-utilities. Regulatory/news items are sourced from web search and should be confirmed against primary company/FDA releases before citation in any contribution.*

*Generated by Diabetes Research Hub automated monitor — 2026-06-06.*
